Skip to main content

Table 2 Demographic data and clinical characteristics of patients with HCC

From: Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study

  HCC in non-cirrhotic NAFLD
n (%)
HCC in cirrhotic NAFLD
n (%)
P value
Total 170 (100) 940 (100)  
Gender    < 0.397
 Male gender 100 (58.8) 520 (55.3)  
 Female gender 70 (41.2) 420 (44.7)  
Age group    0.008
 Age > 65 years 110 (64.7) 700 (74.5)  
 Age 18–65 years 60 (35.3) 240 (25.5)  
Race    < 0.001
 Non-Hispanic white 130 (76.4) 800 (85.1)  
 Non-Hispanic black 20 (11.8) 20 (2.1)  
 Hispanic 20 (11.8) 120 (12.8)  
Comorbidities    
 Obesity 70 (41.2) 490 (52.1) 0.009
 Morbid obesity 20 (11.8) 240 (25.5) < 0.001
 Diabetes mellitus 100 (58.8) 700 (74.5) < 0.001
 Hypertension 140 (82.4) 770 (81.9) 0.891
 Hyperlipidemia 130 (76.5) 590 (62.8) 0.001
Smoker 30 (17.6) 230 (24.5) 0.053
Laboratory data    
 High ALT 110 (64.7) 600 (63.8) 0.827
Medication use    
 Statin 100 (58.8) 450 (47.9) 0.009
 ACEI or ARBs 120 (70.6) 610 (64.9) 0.150
 Metformin 60 (35.3) 390 (41.5) 0.130
 Sulfonylurea 40 (23.5) 280 (39.8) 0.097
 Thiazolidinedione 0 (0) 70 (7.4) < 0.001
 Insulin 80 (47.0) 620 (66.0) < 0.001
Liver decompensation 675 (71.8)